Effects of intensive glucose lowering in type 2 diabetes
The Action to Control Cardiovascular Risk in Diabetes Study Group. Along with the ADVANCE trial, this study provides the most reliable evidence about the effects of intensive glucose control on cardiovascular events
The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559. Along with the ADVANCE trial, this study provides the most reliable evidence about the effects of intensive glucose control on cardiovascular events.
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients
Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417-2428.
Telmisartan, ramipril, or both in patients at high risk for vascular events
The ONTARGET Investigators. This is the first large-scale trial to address the issue of dual RAAS inhibition in patients with diabetes
The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559. This is the first large-scale trial to address the issue of dual RAAS inhibition in patients with diabetes.
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial
ADVANCE Collaborative Group
ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370:829-840.
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
The Advance Collaborative Group. This is the largest trial to date addressing the effects of intensive glucose control in type 2 diabetes, and together with ACCORD provides the most reliable evidence
The Advance Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560-2572. This is the largest trial to date addressing the effects of intensive glucose control in type 2 diabetes, and together with ACCORD provides the most reliable evidence.
Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336:1121-1123.
10-year follow-up of intensive glucose control in type 2 diabetes
This long-term observational follow-up of the UKPDS has raised the possibility that beneficial effects of intensive glucose control may only become apparent many years after the intervention
Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359:1577-1589. This long-term observational follow-up of the UKPDS has raised the possibility that beneficial effects of intensive glucose control may only become apparent many years after the intervention.
Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterollowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371:117-125.
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: A randomized controlled trial
Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008; 300:2134-2141.
The prevention of progression of arterial disease and diabetes (POPADAD) trial: Factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease
doi: 10.1136/bmj.a840
Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337:a1840. doi: 10.1136/bmj.a840.